Synthetic Biologics Inc (NYSEMKT:SYN) has earned an average rating of “Hold” from the six brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $3.92.

A number of research firms have recently commented on SYN. ValuEngine downgraded Synthetic Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Wednesday, August 9th.

Shares of Synthetic Biologics (NYSEMKT SYN) opened at 0.9819 on Friday. Synthetic Biologics has a 52 week low of $0.41 and a 52 week high of $1.90. The firm’s market capitalization is $125.93 million. The stock has a 50 day moving average price of $0.67 and a 200-day moving average price of $0.61.

Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Equities analysts anticipate that Synthetic Biologics will post ($0.17) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Synthetic Biologics Inc (SYN) Receives Consensus Rating of “Hold” from Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/23/synthetic-biologics-inc-syn-receives-consensus-rating-of-hold-from-analysts.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS Group AG increased its holdings in Synthetic Biologics by 10.3% in the 1st quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after purchasing an additional 20,038 shares in the last quarter. Creative Planning increased its holdings in Synthetic Biologics by 65.4% in the 2nd quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after purchasing an additional 70,000 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Synthetic Biologics by 3.1% in the 1st quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after purchasing an additional 7,962 shares in the last quarter. Susquehanna International Group LLP increased its holdings in Synthetic Biologics by 76.4% in the 2nd quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after purchasing an additional 82,030 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Synthetic Biologics by 8,102.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock valued at $639,000 after purchasing an additional 1,115,343 shares in the last quarter.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.